ATE269846T1 - N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen - Google Patents

N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen

Info

Publication number: ATE269846T1
Authority: AT; Austria
Prior art keywords: neuropeptide; treatment; diseases; obesity; receptor ligands
Prior art date: 1998-04-29

Application number

AT99918500T

Other languages

English (en)

Inventor

Scott L Dax

Timothy Walter Lovenberg

James J Mcnally

Allen B Reitz

Mark Andrew Youngman

Original Assignee

Ortho Mcneil Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-29

Filing date

1999-04-12

Publication date

2004-07-15

1999-04-12 Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc

2004-07-15 Application granted granted Critical

2004-07-15 Publication of ATE269846T1 publication Critical patent/ATE269846T1/de

Links

101710151321 Melanostatin Proteins 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
201000010099 disease Diseases 0.000 title abstract 2
239000003446 ligand Substances 0.000 title abstract 2
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title abstract 2
208000008589 Obesity Diseases 0.000 title 1
102100028427 Pro-neuropeptide Y Human genes 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1
102400000064 Neuropeptide Y Human genes 0.000 abstract 2
239000004480 active ingredient Substances 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Furan Compounds (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT99918500T 1998-04-29 1999-04-12 N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen ATE269846T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8341598P	1998-04-29	1998-04-29
PCT/US1999/007971 WO1999055667A1 (en)	1998-04-29	1999-04-12	N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
US09/290,651 US6140354A (en)	1998-04-29	1999-04-12	N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders

Publications (1)

Publication Number	Publication Date
ATE269846T1 true ATE269846T1 (de)	2004-07-15

Family

ID=26769275

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99918500T ATE269846T1 (de)	1998-04-29	1999-04-12	N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen

Country Status (23)

Country	Link
US (1)	US6140354A (de)
EP (1)	EP1076644B1 (de)
JP (1)	JP2004503462A (de)
CN (1)	CN1289475C (de)
AT (1)	ATE269846T1 (de)
AU (1)	AU759313B2 (de)
BG (1)	BG64732B1 (de)
BR (1)	BR9910583A (de)
DE (1)	DE69918296T2 (de)
DK (1)	DK1076644T3 (de)
ES (1)	ES2223170T3 (de)
HU (1)	HUP0102656A3 (de)
ID (1)	ID26128A (de)
IL (1)	IL139227A0 (de)
NZ (1)	NZ507763A (de)
PL (1)	PL194839B1 (de)
PT (1)	PT1076644E (de)
RO (1)	RO120542B1 (de)
RU (1)	RU2219167C2 (de)
TR (1)	TR200100137T2 (de)
TW (1)	TW530043B (de)
WO (1)	WO1999055667A1 (de)
ZA (1)	ZA992951B (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE314371T1 (de)	1998-11-10	2006-01-15	Merck & Co Inc	Spiro-indole als y5-rezeptor antagonisten
AU4659200A (en) *	1999-05-05	2000-11-21	Ortho-Mcneil Pharmaceutical, Inc.	3a,4,5,9b-tetrahydro-1h-benz(e)indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders
US6841552B1 (en)	1999-05-05	2005-01-11	Ortho-Mcneil Pharmaceutical, Inc.	3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders
MXPA02000927A (es) *	1999-07-28	2003-07-14	Johnson & Johnson	Amina y derivados de amida como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de obesidad y otros trastornos.
US20040254153A1 (en) *	1999-11-08	2004-12-16	Pfizer Inc	Compounds for the treatment of female sexual dysfunction
ES2311479T3 (es) *	1999-11-26	2009-02-16	SHIONOGI & CO., LTD.	Antagonistas de npy-y5.
GB0010757D0 (en)	2000-05-05	2000-06-28	Astrazeneca Ab	Chemical compounds
GB0011013D0 (en) *	2000-05-09	2000-06-28	Astrazeneca Ab	Chemical compounds
EP1399553A2 (de)	2000-12-12	2004-03-24	The University of Connecticut	Für zelluläre transportproteine kodierende nukleinsäuren und methoden zur verwendung daraus
US20030082647A1 (en) *	2000-12-12	2003-05-01	Reenan Robert A.	Transporter protein
US6982251B2 (en) *	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
JP4711600B2 (ja)	2001-01-26	2011-06-29	シェーリングコーポレイション	シトステロール血症の処置のための置換アゼチジノン化合物の使用
SI1413331T1 (sl)	2001-01-26	2008-02-29	Schering Corp	Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
US7718802B2 (en)	2001-08-10	2010-05-18	Palatin Technologies, Inc.	Substituted melanocortin receptor-specific piperazine compounds
US7732451B2 (en)	2001-08-10	2010-06-08	Palatin Technologies, Inc.	Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en)	2003-05-01	2008-11-25	Palatin Technologies Inc.	Melanocortin receptor-specific compounds
US7655658B2 (en)	2001-08-10	2010-02-02	Palatin Technologies, Inc.	Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
AU2002331064B2 (en)	2001-08-10	2007-08-23	Palatin Technologies, Inc.	Peptidomimetics of biologically active metallopeptides
US7354923B2 (en) *	2001-08-10	2008-04-08	Palatin Technologies, Inc.	Piperazine melanocortin-specific compounds
GB0121709D0 (en) *	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
GB0121941D0 (en)	2001-09-11	2001-10-31	Astrazeneca Ab	Chemical compounds
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7132415B2 (en)	2001-09-21	2006-11-07	Schering Corporation	Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
BR0212985A (pt) *	2001-09-24	2005-08-30	Imp College Innovations Ltd	Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
CA2403307A1 (en)	2001-10-23	2003-04-23	Neurogen Corporation	Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
DE10157673A1 (de) *	2001-11-24	2003-06-05	Merck Patent Gmbh	Verwendung von N-(Indolcarbonyl-)piperazinderivaten
EP1456171B1 (de) *	2001-12-12	2006-12-20	F. Hoffmann-La Roche Ag	Substituierte cyclohexanderivate
US8058233B2 (en) *	2002-01-10	2011-11-15	Oregon Health And Science University	Modification of feeding behavior using PYY and GLP-1
US6984647B2 (en)	2002-05-17	2006-01-10	Janssen Pharmaceutica N.V.	Aminotetralin-derived urea modulators of vanilloid VR1 receptor
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
CA2504878A1 (en)	2002-11-06	2004-05-27	Schering Corporation	Cholesterol absorption inhibitors for the treatment of demyelination
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
JP4589919B2 (ja)	2003-03-07	2010-12-01	シェーリングコーポレイション	高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN100439361C (zh)	2003-03-07	2008-12-03	先灵公司	取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7727990B2 (en)	2003-05-01	2010-06-01	Palatin Technologies, Inc.	Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en)	2003-05-01	2011-06-28	Palatin Technologies, Inc.	Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en)	2003-05-01	2010-06-01	Palatin Technologies, Inc.	Substituted melanocortin receptor-specific single acyl piperazine compounds
US20070099884A1 (en) *	2003-06-06	2007-05-03	Erondu Ngozi E	Combination therapy for the treatment of diabetes
WO2005000217A2 (en) *	2003-06-06	2005-01-06	Merck & Co., Inc.	Combination therapy for the treatment of dyslipidemia
WO2005028438A1 (ja)	2003-09-22	2005-03-31	Banyu Pharmaceutical Co., Ltd.	新規ピペリジン誘導体
EP1734963A4 (de)	2004-04-02	2008-06-18	Merck & Co Inc	Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
US7709484B1 (en)	2004-04-19	2010-05-04	Palatin Technologies, Inc.	Substituted melanocortin receptor-specific piperazine compounds
WO2005114211A1 (en) *	2004-05-21	2005-12-01	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with g protein-coupled receptor nyp5 (npy5)
ES2325773T5 (es)	2004-11-01	2014-02-24	Amylin Pharmaceuticals, Llc.	Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en) *	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
US20090286723A1 (en)	2005-02-11	2009-11-19	Amylin Pharmaceuticals, Inc.	Hybrid Polypeptides with Selectable Properties
AU2006235200A1 (en) *	2005-04-15	2006-10-19	Regenertech Pty Limited	Use of Neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
NZ562766A (en)	2005-05-30	2011-03-31	Banyu Pharma Co Ltd	Piperidine derivatives as histamine-H3 receptor antagonists
GB0511986D0 (en) *	2005-06-13	2005-07-20	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
EP1916239A4 (de)	2005-08-10	2009-10-21	Banyu Pharma Co Ltd	Pyridolverbindung
BRPI0614649A2 (pt)	2005-08-11	2011-04-12	Amylin Pharmaceuticals Inc	polipeptìdeos hìbridos com propriedades selecionáveis
AU2006282260A1 (en)	2005-08-24	2007-03-01	Msd K.K.	Phenylpyridone derivative
US20090264426A1 (en)	2005-09-07	2009-10-22	Shunji Sakuraba	Bicyclic aromatic substituted pyridone derivative
US8293900B2 (en)	2005-09-29	2012-10-23	Merck Sharp & Dohme Corp	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US20080255084A1 (en)	2005-10-21	2008-10-16	Randy Lee Webb	Combination of Organic Compounds
EP1944301A4 (de)	2005-10-27	2012-01-04	Msd Kk	Neue benzoxathiinderivate
CA2629018C (en)	2005-11-10	2013-12-31	Banyu Pharmaceutical Co., Ltd.	Aza-substituted spiro derivative
AU2007244358B2 (en)	2006-04-28	2012-06-14	Shionogi & Co., Ltd.	Amine derivative having NPY Y5 receptor antagonist activity
US7834017B2 (en)	2006-08-11	2010-11-16	Palatin Technologies, Inc.	Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
EP2698157B1 (de)	2006-09-22	2015-05-20	Merck Sharp & Dohme Corp.	Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
WO2008038692A1 (en)	2006-09-28	2008-04-03	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
TWI428346B (zh) *	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
SA08290668B1 (ar)	2007-10-25	2012-02-12	شيونوجي آند كو.، ليمتد	مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها
CA2705708A1 (en) *	2007-11-14	2009-05-22	Amylin Pharmaceuticals, Inc.	Methods for treating obesity and obesity related diseases and disorders
EP2264026A4 (de)	2008-03-06	2012-03-28	Msd Kk	Alkylaminopyridinderivate
JPWO2009119726A1 (ja)	2008-03-28	2011-07-28	Ｍｓｄ株式会社	メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2726917C (en)	2008-06-04	2018-06-26	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110071129A1 (en)	2008-06-19	2011-03-24	Makoto Ando	Spirodiamine-diaryl ketoxime derivative
EP2321341B1 (de)	2008-07-16	2017-02-22	Synergy Pharmaceuticals Inc.	Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
WO2010013595A1 (ja)	2008-07-30	2010-02-04	萬有製薬株式会社	５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
US8410284B2 (en)	2008-10-22	2013-04-02	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
MX2011004551A (es)	2008-10-30	2011-05-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida.
CA2741672A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2379547A1 (de)	2008-12-16	2011-10-26	Schering Corporation	Pyridopyrimidinderivate und verfahren zu deren anwendung
WO2010075069A1 (en)	2008-12-16	2010-07-01	Schering Corporation	Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US8227618B2 (en)	2009-04-23	2012-07-24	Shionogi & Co., Ltd.	Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
AU2011218830B2 (en)	2010-02-25	2014-07-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en)	2011-02-25	2016-07-26	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9227901B2 (en) *	2012-07-05	2016-01-05	Abbvie Inc.	Process for preparing bicyclic amine derivatives
RU2015106909A (ru)	2012-08-02	2016-09-27	Мерк Шарп И Доум Корп.	Антидиабетические трициклические соединения
BR112015019836A2 (pt)	2013-02-22	2017-07-18	Merck Sharp & Dohme	composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (de)	2013-03-14	2021-11-03	Merck Sharp & Dohme Corp.	Neuartige indolderivate als antidiabetika
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh)	2013-06-05	2021-05-18	博士医疗爱尔兰有限公司	鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
MX389591B (es)	2014-08-29	2025-03-20	Tes Pharma S R L	INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
MX2019004321A (es)	2016-10-14	2019-06-12	Tes Pharma S R L	Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
US11439608B2 (en)	2017-09-25	2022-09-13	Qun Lu	Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
CN118496217A (zh)	2018-11-20	2024-08-16	Tes制药有限责任公司	α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
US12331018B2 (en)	2019-02-13	2025-06-17	Merck Sharp & Dohme Llc	Pyrrolidine orexin receptor agonists
EP3924058B1 (de)	2019-02-13	2026-01-07	Merck Sharp & Dohme LLC	5-alkyl-pyrrolidinorexinrezeptor-agonisten
US12312332B2 (en)	2019-08-08	2025-05-27	Merck Sharp & Dohme Llc	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
US20230365533A1 (en)	2020-08-18	2023-11-16	Merck Sharp & Dohme Llc	Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3718317A1 (de) *	1986-12-10	1988-06-16	Bayer Ag	Substituierte basische 2-aminotetraline
DE69032725T2 (de) *	1989-05-31	1999-04-08	Pharmacia & Upjohn Co., Kalamazoo, Mich.	ZNS-wirksame 8-Heterocyclyl-2-aminotetralin Derivate
FR2701480B1 (fr) *	1993-02-15	1995-05-24	Sanofi Elf	Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
AU1328197A (en) *	1995-12-01	1997-06-19	Synaptic Pharmaceutical Corporation	Aryl sulfonamide and sulfamide derivatives and uses thereof
AU7692996A (en) *	1995-12-01	1997-06-27	Ciba-Geigy Ag	Receptor antagonists

1999
- 1999-04-12 DK DK99918500T patent/DK1076644T3/da active
- 1999-04-12 DE DE69918296T patent/DE69918296T2/de not_active Expired - Fee Related
- 1999-04-12 IL IL13922799A patent/IL139227A0/xx not_active IP Right Cessation
- 1999-04-12 TR TR2001/00137T patent/TR200100137T2/xx unknown
- 1999-04-12 PL PL343771A patent/PL194839B1/pl unknown
- 1999-04-12 JP JP2000545828A patent/JP2004503462A/ja active Pending
- 1999-04-12 EP EP99918500A patent/EP1076644B1/de not_active Expired - Lifetime
- 1999-04-12 WO PCT/US1999/007971 patent/WO1999055667A1/en not_active Ceased
- 1999-04-12 BR BR9910583-7A patent/BR9910583A/pt not_active Application Discontinuation
- 1999-04-12 RO ROA200001058A patent/RO120542B1/ro unknown
- 1999-04-12 ID IDW20002189A patent/ID26128A/id unknown
- 1999-04-12 RU RU2000127036/04A patent/RU2219167C2/ru not_active IP Right Cessation
- 1999-04-12 CN CNB998053937A patent/CN1289475C/zh not_active Expired - Fee Related
- 1999-04-12 NZ NZ507763A patent/NZ507763A/xx unknown
- 1999-04-12 US US09/290,651 patent/US6140354A/en not_active Expired - Lifetime
- 1999-04-12 PT PT99918500T patent/PT1076644E/pt unknown
- 1999-04-12 HU HU0102656A patent/HUP0102656A3/hu unknown
- 1999-04-12 AU AU36400/99A patent/AU759313B2/en not_active Ceased
- 1999-04-12 ES ES99918500T patent/ES2223170T3/es not_active Expired - Lifetime
- 1999-04-12 AT AT99918500T patent/ATE269846T1/de not_active IP Right Cessation
- 1999-04-26 ZA ZA9902951A patent/ZA992951B/xx unknown
- 1999-05-26 TW TW088106980A patent/TW530043B/zh not_active IP Right Cessation
2000
- 2000-10-23 BG BG104877A patent/BG64732B1/bg unknown

Also Published As

Publication number	Publication date
ID26128A (id)	2000-11-23
HUP0102656A3 (en)	2002-12-28
BG64732B1 (bg)	2006-01-31
RO120542B1 (ro)	2006-03-30
BR9910583A (pt)	2001-01-09
NZ507763A (en)	2003-06-30
AU759313B2 (en)	2003-04-10
RU2219167C2 (ru)	2003-12-20
DK1076644T3 (da)	2004-08-30
ES2223170T3 (es)	2005-02-16
CN1289475C (zh)	2006-12-13
PT1076644E (pt)	2004-10-29
PL343771A1 (en)	2001-09-10
JP2004503462A (ja)	2004-02-05
HUP0102656A2 (hu)	2002-03-28
AU3640099A (en)	1999-11-16
DE69918296D1 (de)	2004-07-29
PL194839B1 (pl)	2007-07-31
EP1076644B1 (de)	2004-06-23
IL139227A0 (en)	2001-11-25
CN1298386A (zh)	2001-06-06
WO1999055667A1 (en)	1999-11-04
TW530043B (en)	2003-05-01
EP1076644A1 (de)	2001-02-21
TR200100137T2 (tr)	2001-05-21
ZA992951B (en)	2000-10-26
DE69918296T2 (de)	2005-08-04
BG104877A (en)	2001-06-29
US6140354A (en)	2000-10-31

Legal Events

Date

Code

Title

Description

2005-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1076644

Country of ref document: EP

2009-01-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE269846T1 (de)	2004-07-15	N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
ATE284861T1 (de)	2005-01-15	N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
WO2001062737A3 (en)	2002-03-14	Amino pyrazole derivatives useful for the treatment of obesity and other disorders
NZ516782A (en)	2004-12-24	Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
GEP20053600B (en)	2005-08-10	3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
NO20093464L (no)	2001-11-02	Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
WO2004060882A8 (en)	2005-03-24	Cb 1/cb 2 receptor ligands and their use in the treatment of pain
BR0113838A (pt)	2003-06-03	Derivados de n-fenil-2-pirimidina-amina
MY106315A (en)	1995-04-29	Pharmaceutical agents
MY144992A (en)	2011-12-15	Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
DE60226729D1 (de)	2008-07-03	Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
BR0314797A (pt)	2005-07-26	Derivados da pirimidineamida e o uso dos mesmos
NO20020282D0 (no)	2002-01-18	Nytt difenylpiperidinderivat
ATE386725T1 (de)	2008-03-15	Heterocyclylverbindungen
DE60220055D1 (de)	2007-06-21	4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
ATE369348T1 (de)	2007-08-15	Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ATE400563T1 (de)	2008-07-15	Neue neurokinin-antagonisten zum gebrauch als arzneimittel
SE9902551D0 (sv)	1999-07-02	Novel compounds
BR9811348A (pt)	2000-09-12	Compostos derivados de indol, processo para preparação dos mesmos, e, composições farmacêuticas.
ATE404192T1 (de)	2008-08-15	Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
DE60023154D1 (de)	2006-02-23	Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
DK1492539T3 (da)	2006-10-30	Statin-terapi til forögelse af kognitiv funktion
DE60122764D1 (de)	2006-10-12	Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
DE50212538D1 (de)	2008-09-04	Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzoäcüfluoren-6-carbonsäurederivate als nmda-antagonisten
SE9803277D0 (sv)	1998-09-25	Novel compounds